{"filing":{"accession_number":"0001193125-26-336691","cik":"0001590750","ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"d174744d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526336691/d174744d8k.htm"},"events":[{"id":25539,"run_id":23181,"accession_number":"0001193125-26-336691","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing quarterly financial results for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02 of Form 8-K. The press release reports revenues of $284 thousand, R\u0026D expenses of $71.6 million, SG\u0026A expenses of $55.0 million, and a net loss of $127.1 million, along with cash position of $981.5 million. The disclosure is material as it provides investors with the company's financial performance and cash runway information.","company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26397,"accession_number":"0001193125-26-336691","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing quarterly financial results for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02 of Form 8-K. The press release reports revenues of $284 thousand, R\u0026D expenses of $71.6 million, SG\u0026A expenses of $55.0 million, and a net loss of $127.1 million, along with cash position of $981.5 million. The disclosure is material as it provides investors with the company's financial performance and cash runway information.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:53:04.476365+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26397,"accession_number":"0001193125-26-336691","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing quarterly financial results for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02 of Form 8-K. The press release reports revenues of $284 thousand, R\u0026D expenses of $71.6 million, SG\u0026A expenses of $55.0 million, and a net loss of $127.1 million, along with cash position of $981.5 million. The disclosure is material as it provides investors with the company's financial performance and cash runway information.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:53:04.476365+00:00","company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","filing_date":"2026-08-06"}]}